What is the 13F Pro Quality Score for ABSI?

13F Pro ranks Absci Corp (ABSI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ABSI's current score at https://13fpro.ai/research/ABSI (free sign-up required for the full ranking).

Which hedge funds own the most ABSI stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ABSI include FMR, ARK Investment Management, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ABSI as soon as new 13F filings post.

Where does 13F Pro source ABSI data?

All Absci Corp fundamentals and ownership data come directly from SEC EDGAR. Absci Corp files with the SEC under CIK 1672688. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ABSI in?

Absci Corp (ABSI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ABSI research updated on 13F Pro?

ABSI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Absci Corp(ABSI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1672688 ABSI stock profile & AI dashboard →

13F Pro Quality Score

4.4/100

Rank #2,854 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

2.4/100

Profitability

0.9/100

Balance Sheet

3.0/100

Earnings Quality

30.0/100

Free Cash Flow

0.8/100

Institutional Flow

28.1/100

Revenue Scale

1.1/100

Dilution Risk

1.2/100

ABSI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Absci Corp (ABSI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABSI at 4.4/100 on a 32-signal composite quality model, placing it at rank #2,854 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (0.8) and profitability (0.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Absci Corp reports quarterly revenue of $215.0K, net income of $-29.6M, free cash flow of $-26.3M. Top institutional holders of ABSI by reported 13-F value include FMR, ARK Investment Management, BlackRock,, based on the most recent SEC filings. ABSI trades on the Nasdaq exchange and files with the SEC under CIK 1672688. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABSI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Absci Corp directly from SEC EDGAR. Absci Corp's 13F Pro composite quality score has ranged between 4 and 30 since 2022, currently 4.4 — a declining long-term trajectory across 24 quarterly and live scoring snapshots.

✦

Fun facts about Absci Corp

Quirks, history, and lore behind ABSI — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · listed on Nasdaq · headquartered in Oregon · focused on drug discovery.
2
The Numbers
A pre-revenue, clinical-stage company burning cash in pursuit of a platform — annual losses in the tens of millions and a market cap that swings wildly on partnership news.
3
The History
Founded in the early 2010s, it went public around 2021 during the biotech boom, pitching a future where machines design drugs faster than any human scientist could.
4
The Secret
Its core bet is generative AI married to synthetic biology — the idea that you can design proteins from scratch on a computer and have them work as medicines in the real world.
5
The Lore
It calls its approach "de novo" protein design and has inked research deals with large pharma partners who want to use its AI-powered platform rather than build one themselves.
6
The Giveaway
This Portland-based AI drug design company's very name is a mashup of "absolute" and "science" — and its ticker is four letters that rhyme with that ambition.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$215.0K

Net Income

Q1 2026

$-29.6M

Free Cash Flow

Q1 2026

$-26.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-51.0% YoY

$2.8MFY 2025

FY21 $4.8MFY22 $5.7MFY23 $5.7MFY25 $2.8M

Net Income

-4.2% YoY

$-115.2MFY 2025

FY21 $-101.0MFY22 $-104.9MFY23 $-110.6MFY25 $-115.2M

Operating Income

-4.2% YoY

$-120.3MFY 2025

FY21 $-75.2MFY22 $-106.8MFY23 $-115.5MFY25 $-120.3M

EPS (Diluted)

+30.0% YoY

$-0.84FY 2025

FY21 $-2.08FY22 $-1.15FY23 $-1.20FY25 $-0.84

Total Assets

-0.5% YoY

$216.3MFY 2025

FY21 $426.2MFY22 $321.0MFY23 $217.3MFY25 $216.3M

Total Debt

—FY 2025

FY21 $3.5MFY22 $10.9MFY23 $7.9MFY25 —

Op. Cash Flow

-43.8% YoY

$-92.9MFY 2025

FY21 $-60.6MFY22 $-81.3MFY23 $-64.6MFY25 $-92.9M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$2.8M -51.0%	$5.7M -0.5%	$5.7M +20.2%	$4.8M +0.0%	$4.8M	—
Net Income	$-115.2M -4.2%	$-110.6M -5.4%	$-104.9M -3.9%	$-101.0M -603.4%	$-14.4M	—
Operating Income	$-120.3M -4.2%	$-115.5M -8.2%	$-106.8M -41.9%	$-75.2M -465.7%	$-13.3M	—
EPS (Diluted)	$-0.84 +30.0%	$-1.20 -4.3%	$-1.15 +44.7%	$-2.08 -115.4%	$-0.97	—
Total Assets	$216.3M -0.5%	$217.3M -32.3%	$321.0M -24.7%	$426.2M +381.2%	$88.6M	—
Total Debt	—	$7.9M -27.6%	$10.9M +210.2%	$3.5M	—	—
Operating Cash Flow	$-92.9M -43.8%	$-64.6M +20.5%	$-81.3M -34.2%	$-60.6M -452.4%	$-11.0M	—

AI Insight: ABSI Financial Trends

Absci burns through equity at ~$25M/quarter with near-zero revenue, leaving runway a pressing concern.

• Revenue has flatlined between $0M–$2M across all eight quarters, signaling no commercial traction.

• Operating cash outflow worsened from -$17M in Q2 2024 to -$29M in Q4 2025 and -$26M in Q1 2026.

• Equity eroded from $221M in Q2 2024 to $172M in Q1 2026, a cumulative decline of ~$49M.

⚠ At ~$26M–$29M quarterly cash burn, remaining equity of $172M implies limited runway without new capital raises.

⚠ Debt is effectively absent, but equity dilution risk rises sharply if burn rate does not decrease.

AI Insight: ABSI Ratio Trends

Absci's return metrics have deteriorated sharply with ROIC worsening from -48.3% in Q2 2024 to -71.8% in Q1 2026, signaling deepening capital inefficiency.

• ROIC deteriorated from -48.3% in Q2 2024 to -71.8% in Q1 2026, a 23.5pp worsening over roughly seven quarters.

• ROA declined from -38.7% in Q2 2024 to -60.5% in Q1 2026, indicating assets are generating increasingly larger losses.

• Quarterly swings are wide — ROIC ranged from -48.3% to -72.4% — suggesting lumpy revenue recognition or volatile operating costs.

⚠ ROIC hit -72.4% in Q2 2025, the worst single quarter observed; any repeat would signal accelerating capital destruction.

⚠ D/E data is nearly absent (only 0.02 in Q4 2024); future debt issuance to fund losses would be a key leverage inflection to track.

⚠ OpMargin and NPM are entirely missing across all periods, leaving profitability trajectory impossible to assess from available data.

Get alerted when ABSI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Absci Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ABSI

FMR LLC
$67.7M22,550,997 sh
ARK Investment Management LLC
$41.2M13,726,169 sh
BlackRock, Inc.
$33.8M11,255,194 sh
Redmile Group, LLC
$24.8M8,253,316 sh
STATE STREET CORP
$22.0M7,324,858 sh
ADVANCED MICRO DEVICES INC
$17.1M5,714,285 sh
GEODE CAPITAL MANAGEMENT, LLC
$10.0M3,343,068 sh
Woodline Partners LP
$9.9M3,300,169 sh
AMERIPRISE FINANCIAL INC
$9.5M3,180,141 sh
TWO SIGMA INVESTMENTS, LP
$8.7M2,898,766 sh

Fund	Value	Shares
FMR LLC	$67.7M	22,550,997
ARK Investment Management LLC	$41.2M	13,726,169
BlackRock, Inc.	$33.8M	11,255,194
Redmile Group, LLC	$24.8M	8,253,316
STATE STREET CORP	$22.0M	7,324,858
ADVANCED MICRO DEVICES INC	$17.1M	5,714,285
GEODE CAPITAL MANAGEMENT, LLC	$10.0M	3,343,068
Woodline Partners LP	$9.9M	3,300,169
AMERIPRISE FINANCIAL INC	$9.5M	3,180,141
TWO SIGMA INVESTMENTS, LP	$8.7M	2,898,766

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABT

ABBOTT LABORATORIES

Put ABSI on your watchlist

Track score changes the day Absci Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ABSI a good stock to buy?

13F Pro's AI-powered analysis of Absci Corp (ABSI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABSI are available on the ABSI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ABSI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABSI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Absci Corp's investment landscape.